Glenmark Gets China NMPA Nod for Ryaltris Nasal Spray

Glenmark Specialty S.A.,a subsidiary of Glenmark Pharmaceuticals Ltd. that is fully owned, announced that its innovative nasal spray for allergic rhinitis, Ryaltris Compound Nasal Spray (GSP 301 NS), has received approval from China’s National Medical Products Administration (NMPA).

The authority's nod to the aroide treatment in children as well as in adults, is a major milestone for Glenmark’s respiratory portfolio.

Ryaltris is indicated and thus approved for treatment of moderate to severe seasonal allergic rhinitis in adults and pediatric patients from the age of six and above, and moderate to severe perennial allergic rhinitis in adults and pediatric patients from the age of twelve and above.

The regulatory clearance was accorded to the product without any supplement request, which is a testament to a solid clinical and regulatory basis of the product.

Also Read: Marksans Pharma gains after USFDA clears Goa facility

The agreement enhances Glenmark's commitment to the healthcare industry in the form of leading the way with novel, unique treatment methods to help patients struggling with chronic respiratory diseases. Moreover, it enhances the company's international presence in the allergy and respiratory treatment sector. Thus, it places Ryaltris as a major product in solving the medical needs that have not been addressed in different markets.

Glenmark is not stopping but instead it is doubling down on its commitment to specialty care through its pipeline which will be stocked by research-driven innovations, notably respiratory medicine which happens to be one of the company's core therapeutic areas.

The company is looking to be a provider of advanced treatment solutions that result in better patient outcomes and quality of life, thereby deepening its leadership in respiratory care worldwide.